Last Price$94.32.5%
Market Cap$120.9B
LTM FCF to Net Income
127.6%
5Y avg
123.8%
Medical - Devices industry
median
79.4%
Stock quality & Intrinsic value
6/10
0.2% undervalued
Medtronic plc FCF to Net Income
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Apr'05 | Apr'06 | Apr'07 | Apr'08 | Apr'09 | Apr'10 | Apr'11 | Apr'12 | Apr'13 | Apr'14 | Apr'15 | Apr'16 | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF to Net Income | 131.2% | 37.8% | 81.5% | 129.2% | 148.2% | 112.8% | 103.1% | 106.5% | 127.7% | 148.9% | 161.9% | 117.9% | 139.8% | 116.8% | 126.3% | 125.3% | 134.6% | 118.1% | 121.0% | 141.5% |
Overvalued or undervalued?
Check the intrinsic value for MDT
and see if it's the right time to invest.
Medtronic plc (MDT) FCF to Net Income comparison analysis
General
LTM FCF to Net Income
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Medtronic plcMDT
127.6%
3.6%
(2.1%)
11.4%
Median Peer Set
97.6%
5.6%
126.3%
12.7%
Align Technology, Inc.ALGN
147.8%
3.4%
26.0%
11.5%
Zimmer Biomet Holdings, Inc.ZBH
125.2%
6.5%
253.2%
13.8%
STERIS plcSTE
120.6%
3.6%
257.9%
7.4%
Boston Scientific CorporationBSX
117.3%
17.6%
16.7%
11.1%
Stryker CorporationSYK
116.5%
10.2%
(5.8%)
13.2%
DexCom, Inc.DXCM
78.8%
11.3%
(1.4%)
14.3%
Insulet CorporationPODD
72.4%
30.0%
4,364.6%
12.2%
Abbott LaboratoriesABT
47.4%
4.6%
134.5%
31.9%
Edwards Lifesciences CorporationEW
12.1%
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
(31.1%)
(0.8%)
118.1%
(3.9%)
MDT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Apr'05 | Apr'06 | Apr'07 | Apr'08 | Apr'09 | Apr'10 | Apr'11 | Apr'12 | Apr'13 | Apr'14 | Apr'15 | Apr'16 | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 10,054.6 10.6% | 11,292.0 12.3% | 12,299.0 8.9% | 13,515.0 9.9% | 14,599.0 8.0% | 15,817.0 8.3% | 15,933.0 0.7% | 16,184.0 1.6% | 16,590.0 2.5% | 17,005.0 2.5% | 20,261.0 19.1% | 28,833.0 42.3% | 29,710.0 3.0% | 29,953.0 0.8% | 30,557.0 2.0% | 28,913.0 (5.4%) | 30,117.0 4.2% | 31,686.0 5.2% | 31,227.0 (1.4%) | 32,364.0 3.6% |
| Cost of Goods Sold (COGS) | 2,446.4 | 2,815.3 | 3,168.0 | 3,446.0 | 3,518.0 | 3,812.0 | 3,912.0 | 3,889.0 | 4,126.0 | 4,333.0 | 6,309.0 | 9,142.0 | 9,291.0 | 9,055.0 | 9,155.0 | 9,424.0 | 10,483.0 | 10,145.0 | 10,719.0 | 11,216.0 |
% margin | 7,608.2 75.7% | 8,476.7 75.1% | 9,131.0 74.2% | 10,069.0 74.5% | 11,081.0 75.9% | 12,005.0 75.9% | 12,021.0 75.4% | 12,295.0 76.0% | 12,464.0 75.1% | 12,672.0 74.5% | 13,952.0 68.9% | 19,691.0 68.3% | 20,419.0 68.7% | 20,898.0 69.8% | 21,402.0 70.0% | 19,489.0 67.4% | 19,634.0 65.2% | 21,541.0 68.0% | 20,508.0 65.7% | 21,148.0 65.3% |
| Operating Expenses | 4,164.9 | 4,772.3 | 5,392.0 | 5,982.0 | 6,903.0 | 7,740.0 | 7,041.0 | 7,899.0 | 7,694.0 | 7,854.0 | 9,395.0 | 13,731.0 | 14,106.0 | 14,555.0 | 14,770.0 | 14,267.0 | 14,739.0 | 15,633.0 | 14,678.0 | 16,129.0 |
| Research & Development Expenses (R&D) | 951.3 | 1,112.9 | 1,239.0 | 1,275.0 | 1,355.0 | 1,483.0 | 1,508.0 | 1,490.0 | 1,557.0 | 1,477.0 | 1,640.0 | 2,224.0 | 2,193.0 | 2,253.0 | 2,330.0 | 2,331.0 | 2,493.0 | 2,746.0 | 2,696.0 | 2,735.0 |
| Selling, General & Administrative Expenses (SG&A) | 3,213.6 | 3,659.4 | 4,153.0 | 4,707.0 | 5,152.0 | 5,789.0 | 5,533.0 | 6,074.0 | 5,698.0 | 5,847.0 | 6,904.0 | 9,469.0 | 9,711.0 | 9,974.0 | 10,418.0 | 10,109.0 | 10,148.0 | 10,292.0 | 10,415.0 | 10,736.0 |
% margin | 2,543.5 25.3% | 3,161.3 28.0% | 3,515.0 28.6% | 2,885.0 21.3% | 2,811.0 19.3% | 4,371.0 27.6% | 4,173.0 26.2% | 4,696.0 29.0% | 4,639.0 28.0% | 4,084.0 24.0% | 3,766.0 18.6% | 5,291.0 18.4% | 5,330.0 17.9% | 6,651.0 22.2% | 6,268.0 20.5% | 4,791.0 16.6% | 4,484.0 14.9% | 5,752.0 18.2% | 5,485.0 17.6% | 5,144.0 15.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 364.0 | 188.0 | 156.0 | 172.0 | 200.0 | 237.0 | 271.0 | 386.0 | 431.0 | 366.0 | 397.0 | 1,444.0 | 300.0 | 192.0 | 367.0 | 386.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 255.0 | 217.0 | 246.0 | 450.0 | 149.0 | 388.0 | 379.0 | 666.0 | 1,386.0 | 1,094.0 | 1,146.0 | 1,444.0 | 1,092.0 | 925.0 | 553.0 | 636.0 | 719.0 |
| Pre-tax Income | 2,543.5 | 3,161.3 | 3,515.0 | 2,885.0 | 2,594.0 | 3,969.0 | 3,723.0 | 4,145.0 | 4,251.0 | 3,705.0 | 3,486.0 | 4,336.0 | 4,602.0 | 5,675.0 | 5,197.0 | 4,055.0 | 3,895.0 | 5,517.0 | 5,364.0 | 4,837.0 |
% effective tax rate | 739.6 29.1% | 614.6 19.4% | 713.0 20.3% | 654.0 22.7% | 425.0 16.4% | 870.0 21.9% | 627.0 16.8% | 730.0 17.6% | 784.0 18.4% | 640.0 17.3% | 811.0 23.3% | 798.0 18.4% | 578.0 12.6% | 2,580.0 45.5% | 547.0 10.5% | (751.0) (18.5%) | 265.0 6.8% | 456.0 8.3% | 1,580.0 29.5% | 1,133.0 23.4% |
% margin | 1,803.9 17.9% | 2,546.7 22.6% | 2,802.0 22.8% | 2,231.0 16.5% | 2,169.0 14.9% | 3,099.0 19.6% | 3,096.0 19.4% | 3,617.0 22.3% | 3,467.0 20.9% | 3,065.0 18.0% | 2,675.0 13.2% | 3,538.0 12.3% | 4,028.0 13.6% | 3,104.0 10.4% | 4,631.0 15.2% | 4,789.0 16.6% | 3,606.0 12.0% | 5,039.0 15.9% | 3,758.0 12.0% | 3,676.0 11.4% |
| EPS | 1.49 | 2.11 | 2.44 | 1.97 | 1.85 | 2.80 | 2.87 | 3.43 | 3.40 | 3.06 | 2.44 | 2.51 | 2.92 | 2.29 | 3.44 | 3.57 | 2.68 | 3.75 | 2.83 | 2.77 |
| Diluted EPS | 1.48 | 2.09 | 2.41 | 1.95 | 1.84 | 2.79 | 2.86 | 3.41 | 3.37 | 3.02 | 2.41 | 2.48 | 2.89 | 2.27 | 3.41 | 3.54 | 2.66 | 3.73 | 2.82 | 2.76 |
% margin | 3,061.9 30.5% | 4,172.8 37.0% | 4,322.0 35.1% | 3,631.0 26.9% | 3,510.0 24.0% | 5,143.0 32.5% | 5,058.0 31.7% | 5,327.0 32.9% | 5,538.0 33.4% | 5,645.0 33.2% | 6,278.0 31.0% | 8,539.0 29.6% | 9,027.0 30.4% | 9,189.0 30.7% | 9,368.0 30.7% | 7,825.0 27.1% | 8,192.0 27.2% | 9,554.0 30.2% | 8,475.0 27.1% | 8,203.0 25.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Medtronic plc's FCF to Net Income?
As of today, Microsoft Corp's last 12-month FCF to Net Income is 127.6%, based on the financial report for Jan 24, 2025 (Q1’2025). The average annual FCF to Net Income for Medtronic plc have been 120.9% over the past three years, and 130.0% over the past five years.
2) Is Medtronic plc's FCF to Net Income Good?
As of today, Medtronic plc's FCF to Net Income is 127.6%, which is higher than industry median of 79.4%. It indicates that Medtronic plc's FCF to Net Income is Good.